Skip to main content
Genomtec S.A. logo

Genomtec S.A. — Investor Relations & Filings

Ticker · GMT ISIN · PLGNMTC00017 LEI · 259400ND13Y44ADMG554 WAR Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2026-05-22 Share Issue/Capital Cha…
Country PL Poland
Listing WAR GMT

About Genomtec S.A.

https://genomtec.com/en/

Genomtec S.A. is a technology company specializing in the development of mobile platforms for rapid molecular diagnostics. The company's flagship product is Genomtec ID, a portable point-of-care system for genetic testing that combines the amplification and detection of specific DNA and RNA fragments. This technology enables fast and accurate analysis without requiring specialized laboratory infrastructure or personnel. A key application is the CE-IVD certified GenomtecID Respiratory Panel 5-Plex (RP5-PLEX), which detects viruses and bacteria causing respiratory tract infections. The company has also organized its core technologies, the Genomtec ID platform and the OncoSNAAT oncology project, into separate special purpose vehicles to facilitate strategic development and potential M&A processes.

Recent filings

Filing Released Lang Actions
Zawarcie porozumienia ws. ustalenia liczby i ceny sprzedaży istniejących akcji Spółki w ramach oferty publicznej prowadzonej przez Akcjonariusza - Content (PL)
Share Issue/Capital Change Classification · 89% confidence The document is a current report by Genomtec S.A. announcing the results of an accelerated book-building process for the sale of existing shares and setting the terms of a new share issuance under an investment agreement. It details the number of shares sold, the sale price, and the issue price for new shares. This is a capital change event involving a share offering, fitting the “Share Issue/Capital Change” category.
2026-05-22 Polish
zal01_FormularzA_TG.pdf
Major Shareholding Notification Classification · 90% confidence The document is a notification by a shareholder (akcjonariusz) under Articles 69 and 69a of the Polish Public Offering Act, disclosing changes in shareholding levels (acquisition of 7,000 shares and crossing a 5% ownership threshold). It provides detailed before‐and‐after share counts and percentages. This matches the definition of a Major Shareholding Notification (Code: MRQ).
2026-05-21 Polish
Zawiadomienie o zmianie stanu posiadania akcji Spółki - Content (PL)
Major Shareholding Notification Classification · 95% confidence The document is a current report notifying of a receipt of a notification under Article 69(1)(1) of the Polish Act on Public Offering regarding a change in ownership of company shares by Mr. Tomasz Gaszyński. This aligns with a Major Shareholding Notification, as it informs on changes in significant share ownership thresholds. It is not a director’s own share transaction report or share buyback, but a statutory threshold notification by a shareholder.
2026-05-21 Polish
zal01_zawiadomienie_o_rozpoczeciu_ABB.pdf
Capital/Financing Update Classification · 100% confidence The document is a notification from a shareholder (5HT Fundacja Rodzinna) to Genomtec S.A. about the fulfillment of conditions and the commencement of an Accelerated Book Building (ABB) process for a public offering of shares. It details the number of shares to be sold, the regulatory framework, the planned timeline, and disclaimers about the nature of the notification. There are no financial statements, earnings data, or management commentary. The document is an announcement related to a capital market transaction, specifically a financing activity involving a share offering. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-05-18 Polish
Rozpoczęcie przez Akcjonariusza oferty publicznej akcji istniejących Spółki w trybie przyspieszonego budowania księgi popytu - Content (PL)
Capital/Financing Update Classification · 85% confidence The document is a current report disclosing that a major shareholder has notified the company about the fulfillment of conditions under an investment agreement and the start of a public offering of existing shares, with proceeds reinvested into a new share issue. This is an update on financing and capital structure activity rather than a formal financial report, fitting the Capital/Financing Update category.
2026-05-18 Polish
zal02_2_Projekty_uchwal_NWZ.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document consists of resolutions from an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie) of Genomtec S.A. dated June 3, 2026. The content includes the election of the Chairman of the meeting, adoption of the agenda, and appointment of a new member to the Supervisory Board (Rada Nadzorcza). These are typical materials related to shareholder meetings and their decisions. There is no financial data, no audit information, no earnings or interim report, nor any presentation or legal proceeding details. The document is not a report itself but rather the official resolutions passed at a general meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting, including appointments to the board. The document length is short (3371 characters), but it contains the actual resolutions, not just an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is DVA with high confidence.
2026-05-07 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.